Get all your news in one place.
100's of premium titles.
One app.
Start reading
Al Jazeera
Al Jazeera
Health

Data shows drug slowing Alzheimer’s but doubts over effect remain

The new drug was developed by firms Biogen and Eisai [File: Steven Senne/AP Photo]

Experts have welcomed full data showing an experimental drug can slow cognitive decline in Alzheimer’s patients, but warned improvements were comparatively small and said it remained unclear how much difference it might make in people’s lives.

Japanese drugmaker Eisai and its United States partner Biogen had announced in September that preliminary data from a trial of lecanemab found it slowed cognitive decline by 27 percent across an 18-month period.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.